Israeli generics giant Teva Pharmaceutical Industries Ltd (NYSE:TEVA) has reached a settlement with Perrigo Pharmaceutical (NYSE: PRGO) and privately-held Catalent Pharma Solutions with respect to four patents for Teva’s ProAir HFA (albuterol sulfate) inhalation aerosol product. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) net profit margin is 6.80% and weekly performance is 787%. On last trading day company shares ended up $52.59. Analysts mean target price for the company is $57.09. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) distance from 50-day simple moving average is 4.01%.
After an M&A packed morning, Abbott Laboratories (NYSE:ABT) announced on Monday afternoon that it is acquiring Russian Pharmaceutical company Veropharm. The definitive agreement will see Abbott Labs acquire Limited Liability Company Garden Hills, which has a controlling interest in Veropharm. The price of the sale will be between $395 million and $495 million, depending on how much of Veropharm Garden Hills owns at the time. Garden Hills currently owns 80% of Veropharm, but is expected to own 95% by the time the deal closes. Abbott Laboratories (NYSE:ABT) shares fell -0.29% in last trading session and ended the day on $40.73. ABT Gross Margin is 54.00% and its return on assets is 6.90%. Abbott Laboratories (NYSE:ABT) quarterly performance is 6.62%.
Liberum Capital restated their hold rating on shares ofGlaxoSmithKline plc (NYSE:GSK) in a report released on Friday.GlaxoSmithKline plc (ADR) (NYSE:GSK) shares moved down -1.23% in last trading session and was closed at $53.87, while trading in range of $53.70-$53.91. GlaxoSmithKline plc (ADR) (NYSE:GSK) year to date performance is 3.44%.
Biogen Idec Inc. (NASDAQ:BIIB) and AbbVie are planning to file forms with regulatory agencies to further develop DAC HYP. They will release more detailed DECIDE results at upcoming medical conferences. Biogen Idec Inc (NASDAQ:BIIB) ended the last trading day at $313.46. Company weekly volatility is calculated as 2.12% and price to cash ratio as 59.00. Biogen Idec Inc (NASDAQ:BIIB) showed a positive weekly performance of 1.78%.
U.K.-based Reckitt Benckiser Group PLC, the maker of d-Con, struck a truce with the U.S. Environmental Protection Agency over a plan to ban sales of the rat poison, which has been linked to accidental exposures in children and wildlife. Under the agreement, the company said Friday that at the end of this year it will stop making the type of bait pellets the EPA opposed and replace the products in 2015 with a line approved by the agency for home use. The new formula likely will require mice and rats to eat larger amounts of the bait to be effective. Reckitt Benckiser Group Plc-ADR (OTCMKTS:RBGLY) On last trading day company shares ended up $17.89.